Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib and Pembrolizumab for Metastatic PD-L1+ NSCLC
NCT03425006Phase 2Terminated
- Sponsor
- University of Pennsylvania
- Start
- Jun 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of itacitinib in non-small cell lung cancer (NSCLC), sponsored by University of Pennsylvania. Started Jun 2018; status: terminated.
02
Drugs
itacitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03425006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425006.